{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T01:43:55Z","timestamp":1777081435928,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ejogrb.2020.05.043","type":"journal-article","created":{"date-parts":[[2020,5,31]],"date-time":"2020-05-31T17:40:49Z","timestamp":1590946849000},"page":"7-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2"],"prefix":"10.1016","volume":"252","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6516-1444","authenticated-orcid":false,"given":"Kristina","family":"Gemzell-Danielsson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oskari","family":"Heikinheimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janos","family":"Zatik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1836-1579","authenticated-orcid":false,"given":"Robert","family":"Poka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Rechberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Hudecek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Petersdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Faustmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Groettrup-Wolfers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"319","key":"10.1016\/j.ejogrb.2020.05.043_bib0005","first-page":"e1","article-title":"The impact of uterine leiomyomas: a national survey of affected women","volume":"209","author":"Borah","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0010","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1067\/mob.2003.99","article-title":"High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence","volume":"188","author":"Baird","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0015","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/1471-0528.14640","article-title":"Epidemiology of uterine fibroids: a systematic review","volume":"124","author":"Stewart","year":"2017","journal-title":"BJOG"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1701-2163(15)30338-8","article-title":"The management of uterine leiomyomas","volume":"37","author":"Vilos","year":"2015","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0025","first-page":"615","article-title":"Clinical presentation of fibroids","volume":"22","author":"Gupta","year":"2008","journal-title":"Pract Res Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0030","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1089\/jwh.2013.4334","article-title":"The burden of uterine fibroids for African-American women: results of a national survey","volume":"22","author":"Stewart","year":"2013","journal-title":"J Womens Health (Larchmt)."},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0035","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jpsychores.2014.12.016","article-title":"Beyond the physical: a qualitative assessment of the burden of symptomatic uterine fibroids on women\u2019s emotional and psychosocial health","volume":"78","author":"Ghant","year":"2015","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0040","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1185\/03007995.2015.1107534","article-title":"Burden of symptomatic uterine fibroids in Canadian women: a cohort study","volume":"32","author":"Laberge","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0045","first-page":"2936","article-title":"A single baseline ultrasound assessment of fibroid presence and size is strongly predictive of future uterine procedure: 8-year follow-up of randomly sampled premenopausal women aged 35-49 years","volume":"30","author":"Baird","year":"2015","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149631","article-title":"Medical therapies for uterine fibroids - a systematic review and network meta-analysis of randomised controlled trials","volume":"11","author":"Gurusamy","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0055","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.fertnstert.2016.11.027","article-title":"Rewriting the script: time to rethink the indications for myoma surgery","volume":"107","author":"Donnez","year":"2017","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0060","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMra1209993","article-title":"Uterine fibroids","volume":"369","author":"Bulun","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0065","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/14728222.2016.1180368","article-title":"Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies","volume":"20","author":"Wagenfeld","year":"2016","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.fertnstert.2014.10.038","article-title":"Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids","volume":"103","author":"Donnez","year":"2015","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0075","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":"Ulipristal acetate versus leuprolide acetate for uterine fibroids","volume":"366","author":"Donnez","year":"2012","journal-title":"NEJM"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0080","series-title":"Press release: fibristal\u00ae the first and only medication indicated for uterine fibroids, receives approval from Health Canada for long term intermittent treatment","author":"AllerganPharmaCo","year":"2016"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0085","author":"GedeonRichter"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0090","author":"EMA"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0095","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/17425255.2018.1506766","article-title":"Uterine fibroid therapy: the pharmacokinetic considerations","volume":"14","author":"Ali","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0100","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cct.2017.02.002","article-title":"Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids","volume":"55","author":"Seitz","year":"2017","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0105","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/humrep\/dew140","article-title":"Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women","volume":"31","author":"Schuett","year":"2016","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0110","series-title":"3rd Congress of the Society of Endometriosis and Uterine Disorders Congress","article-title":"Effects of progesterone receptor modulator vilaprisan on ovarian activity in healthy women: poster 17","author":"Chang","year":"2017"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0115","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1093\/humrep\/det247","article-title":"BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies","volume":"28","author":"Wagenfeld","year":"2013","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0120","article-title":"Vilaprisan in women with uterine fibroids: randomized phase 2b ASTEROID 1 study","author":"Bradley","year":"2018","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0125","series-title":"Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan (VPR) for the treatment of patients with uterine fibroids by exposure\u2013response modeling and simulation","author":"Ploeger","year":"2017"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0130","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.fertnstert.2013.10.051","article-title":"Validation of a new menstrual pictogram (superabsorbent polymer-c version) for use with ultraslim towels that contain superabsorbent polymers","volume":"101","author":"Magnay","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0135","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ijgo.12666","article-title":"The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions","volume":"143","author":"Munro","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0140","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"Ulipristal acetate versus placebo for fibroid treatment before surgery","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0145","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/cmdc.201800487","article-title":"Discovery of vilaprisan (BAY 1002670), a highly potent and selective progesterone receptor modulator optimized for gynecologic therapies","volume":"13","author":"Moeller","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0150","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1517\/13543784.17.4.469","article-title":"Investigational developments for the treatment of progesterone-dependent diseases","volume":"17","author":"Moller","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0155","series-title":"Press release: repros requests lift of clinical hold on Proellex","author":"Repros","year":"2010"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0160","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1208\/s12248-011-9304-7","article-title":"Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance","volume":"13","author":"Morris","year":"2011","journal-title":"AAPS J"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0165","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1177\/1933719114549850","article-title":"The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids","volume":"22","author":"Pohl","year":"2015","journal-title":"Reprod Sci"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0170","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2174\/0929867321666141112122118","article-title":"Should the incorporation of structural alerts be restricted in drug design? An analysis of structure-toxicity trends with aniline-based drugs","volume":"22","author":"Kalgutkar","year":"2015","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0175","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13321-015-0053-y","article-title":"Data-driven identification of structural alerts for mitigating the risk of drug-induced human liver injuries","volume":"7","author":"Liu","year":"2015","journal-title":"J Cheminform"},{"key":"10.1016\/j.ejogrb.2020.05.043_bib0180","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s40262-017-0607-4","article-title":"Characterization of the pharmacokinetics of vilaprisan: bioavailability, excretion, biotransformation, and drug-drug interaction potential","volume":"57","author":"Schultze-Mosgau","year":"2018","journal-title":"Clin Pharmacokinet"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211520303262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211520303262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T05:47:46Z","timestamp":1759556866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211520303262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":36,"alternative-id":["S0301211520303262"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2020.05.043","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2020.05.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}